Clinical Trial Update: mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating mFOLFOX7 plus camrelizumab and apatinib for advanced hepatocellular carcinoma (CNLC Stage III) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)
• mFOLFOX7 (modified FOLFOX7)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Stage III Hepatocellular Cancer (CNLC Staging) | Phase 2 | Status: RECRUITING